1-[5-[[[(4-chlorophenyl)amino]carbonyl]amino]-o-tolyl]-3-(p-tolyl)urea

Chemical Class

N-Phenylureas

Primary Use

Treatment for multiple myeloma and myelodysplastic syndromes

Mechanism of Action

Affects the immune system and inhibits the growth of cancerous cells

Immunomodulatory Properties

Believed to contribute to therapeutic effects

Antiangiogenic Properties

Believed to contribute to therapeutic effects

Precautions

Increased risk of severe and life-threatening birth defects when used during pregnancy

Side Effects

Associated with several side effects (specific side effects not provided in the material)

Derivative

Thalidomide

Chemical Structure

1-[5-[[[(4-chlorophenyl)amino]carbonyl]amino]-o-tolyl]-3-(p-tolyl)urea

General Description

1-[5-[[[(4-chlorophenyl)amino]carbonyl]amino]-o-tolyl]-3-(p-tolyl)urea is a chemical compound that is also known by its trade name, Lenalidomide. It is a derivative of thalidomide and is primarily used as a treatment for multiple myeloma and myelodysplastic syndromes. It works by affecting the immune system and inhibiting the growth of cancerous cells. The compound is a member of the class of organic compounds known as N-phenylureas, which are ureas in which the nitrogen is linked to a phenyl group. The precise mechanism of action of 1-[5-[[[(4-chlorophenyl)amino]carbonyl]amino]-o-tolyl]-3-(p-tolyl)urea is not fully understood, but it is believed to have immunomodulatory and antiangiogenic properties, which contribute to its therapeutic effects. However, the use of this compound is associated with several side effects and precautions, such as an increased risk of severe and life-threatening birth defects when used during pregnancy.